Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women of 18 years of age or older.~* T-score by Dual X-ray Absorptiometry (DXA) between -1,0 og -3,5~* Patients from The North Jutland Region diagnosed with primary hyperparathyroidism at the Department of Endocrinology, Aalborg University Hospital. (Hypercalcaemia measured at two different time-points and simultaneous elevated/inappropriately high PTH, and exclusion of differential diagnosis.)~Exclusion Criteria:~* Medical history of diseases leading to hypercalcaemia other than Primary Hyperparathyroidism.~* Patients being treated with Denosumab or Cinacalcet prior to inclusion or previously treated with Denosumab or Cinacalcet.~* Moderately - Severely decreased liver function (alanine aminotransferase \>250u/l, gamma-glutamyl transferase\>150u/l, Bilirubin \>30)~* Acute myocardial infarction or apoplexia in the 3 months before inclusion.~* Medical record of heart failure~* Risk factors of prolonged corrected QT interval (QTc).~* Open lesions from oral surgery.~* Primary diseases of the bone other than osteoporosis.~* Patients suffering from kidney disease or renal failure.~* Patients under treatment with thiazide or lithium.~* Medical record of generalized seizures or epilepsy.~* Active malignant disease.~* Known allergies towards the specified medicinal products (IMPs).~* Pregnancy or breastfeeding.~* Fertile women who do not agree to the usage of effective contraception.~* Other circumstances, evaluated by the responsible investigator, making the subject unsuitable for participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined treatment. (Type: EXPERIMENTAL): 20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
- Monotherapy (Type: ACTIVE_COMPARATOR): 20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
- Placebo (Type: PLACEBO_COMPARATOR): 20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).